Nanoform Finland Plc., the medicine performance-enhancing company, announced that one of its leading nanoformulation drug products had received promising relative bioavailability results from its clinical study of nanocrystalline-enabled enzalutamide (nanoenzalutamide) tablet formulation.

Medicine performance-enhancing specialists Nanoform announced it had completed a relative bioavailability study of its nanocrystalline enabled enzalutamide as an alternative to an amorphous solid dispersion formulation of Xtandi®, the leading prescribed androgen receptor inhibitor approved to treat prostate cancer.

To expedite product development and accelerate time-to-market, Colorcon announced its HyperStart C2C™ Smart Formulation Hub, which helps formulators minimize the need for repetitive formulation iterations.